A major epidemiological finding reveals the remarkable potency of visceral fat reduction: each 1% decrease in visceral fat correlates with measurable, sustained improvements in insulin sensitivity that persist for 10 years. This remarkable stability contrasts sharply with the fleeting benefits of other fat reductions, where liver fat loss showed only 4% diabetes risk reduction, pancreatic fat loss 2%, and subcutaneous fat loss essentially zero protection over the same period. The study’s 278 participants demonstrated that this metabolic advantage remained intact despite complete return to baseline body weight, suggesting a biological mechanism that preserves insulin function independent of total adiposity. These quantifiable long-term metabolic gains underscore visceral fat’s unique pathophysiological role in diabetes development and represent a paradigm shift in understanding how targeted fat loss drives persistent health benefits. Read the full article on GMJ Newsroom.
Was this article helpful?
